Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in
RAS
mutant cancers
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 9, Issue 392, Pages eaal5148
Publisher
American Association for the Advancement of Science (AAAS)
Online
2017-08-18
DOI
10.1126/scitranslmed.aal5148
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Proteogenomics connects somatic mutations to signalling in breast cancer
- (2016) Philipp Mertins et al. NATURE
- Functional characterization of somatic mutations in cancer using network-based inference of protein activity
- (2016) Mariano J Alvarez et al. NATURE GENETICS
- Functional annotation of rare gene aberration drivers of pancreatic cancer
- (2016) Yiu Huen Tsang et al. Nature Communications
- MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer
- (2015) K. E. Hew et al. CLINICAL CANCER RESEARCH
- Integrative analysis of RNA, translation, and protein levels reveals distinct regulatory variation across humans
- (2015) Can Cenik et al. GENOME RESEARCH
- Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma
- (2015) Lawrence N. Kwong et al. JOURNAL OF CLINICAL INVESTIGATION
- FOXM1: An emerging master regulator of DNA damage response and genotoxic agent resistance
- (2014) Stefania Zona et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors
- (2014) Lydia W.T. Cheung et al. CANCER CELL
- Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor
- (2014) C. H. Kugel et al. CANCER RESEARCH
- Forkhead Transcription Factor FOXO3a Levels Are Increased in Huntington Disease Because of Overactivated Positive Autofeedback Loop
- (2014) Kaja Kannike et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Genome-wide transcriptome profiling of homologous recombination DNA repair
- (2014) Guang Peng et al. Nature Communications
- A pan-cancer proteomic perspective on The Cancer Genome Atlas
- (2014) Rehan Akbani et al. Nature Communications
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- DNA Double-Strand Break Repair Pathway Choice Is Directed by Distinct MRE11 Nuclease Activities
- (2013) Atsushi Shibata et al. MOLECULAR CELL
- Genome-wide analysis of FOXO3 mediated transcription regulation through RNA polymerase II profiling
- (2013) A. Eijkelenboom et al. Molecular Systems Biology
- Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer
- (2013) N Panupinthu et al. ONCOGENE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Evaluating cell lines as tumour models by comparison of genomic profiles
- (2013) Silvia Domcke et al. Nature Communications
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
- (2012) Taru Muranen et al. CANCER CELL
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
- (2012) Haoqiang Ying et al. CELL
- Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis
- (2012) O. Takahashi et al. CLINICAL CANCER RESEARCH
- Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer
- (2012) H. Liang et al. GENOME RESEARCH
- Ovarian low-grade serous carcinoma: A comprehensive update
- (2012) Ivan Diaz-Padilla et al. GYNECOLOGIC ONCOLOGY
- β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer
- (2012) Stephan P Tenbaum et al. NATURE MEDICINE
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
- (2012) Lauren Averett Byers et al. Cancer Discovery
- MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers
- (2011) E. Vilar et al. CANCER RESEARCH
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer
- (2011) C T Karadedou et al. ONCOGENE
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Expression of Autotaxin and Lysophosphatidic Acid Receptors Increases Mammary Tumorigenesis, Invasion, and Metastases
- (2009) Shuying Liu et al. CANCER CELL
- Synthetic Lethality — A New Direction in Cancer-Drug Development
- (2009) J. Dirk Iglehart et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients
- (2008) J. W. Tyner et al. BLOOD
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now